Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RARE Stock Forecast 2025-2026
$37.35
Current Price
$3.51B
Market Cap
Buy 19
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to RARE Price Targets
+264.1%
To High Target of $136.00
+130.3%
To Median Target of $86.00
+4.4%
To Low Target of $39.00
RARE Price Momentum
-0.4%
1 Week Change
0.0%
1 Month Change
-1.8%
1 Year Change
-11.2%
Year-to-Date Change
-38.1%
From 52W High of $60.37
+26.2%
From 52W Low of $29.59
📊 TOP ANALYST CALLS
Did RARE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Ultragenyx is one of their latest high-conviction picks.
Latest RARE Stock Price Targets & Analyst Predictions
Based on our analysis of 32 Wall Street analysts, RARE has a bullish consensus with a median price target of $86.00 (ranging from $39.00 to $136.00). Currently trading at $37.35, the median forecast implies a 130.3% upside. This outlook is supported by 19 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Whitney Ijem at Canaccord Genuity, projecting a 264.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RARE Analyst Ratings
19
Buy
1
Hold
0
Sell
RARE Price Target Range
Low
$39.00
Average
$86.00
High
$136.00
Current: $37.35
Latest RARE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RARE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 28, 2025 | William Blair | Sami Corwin | Outperform | Initiates | $65.00 |
| May 9, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Maintains | $65.00 |
| Mar 27, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $117.00 |
| Mar 17, 2025 | Piper Sandler | Allison Bratzel | Overweight | Maintains | $115.00 |
| Feb 26, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $118.00 |
| Feb 18, 2025 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $136.00 |
| Feb 18, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $95.00 |
| Feb 14, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $95.00 |
| Jan 22, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $118.00 |
| Jan 13, 2025 | Wedbush | Laura Chico | Neutral | Reiterates | $48.00 |
| Jan 13, 2025 | Piper Sandler | Christopher Raymond | Overweight | Maintains | $140.00 |
| Dec 24, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $95.00 |
| Dec 20, 2024 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $88.00 |
| Nov 21, 2024 | JP Morgan | Anupam Rama | Overweight | Maintains | $102.00 |
| Nov 12, 2024 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $121.00 |
| Nov 6, 2024 | RBC Capital | Luca Issi | Outperform | Reiterates | $77.00 |
| Nov 6, 2024 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $121.00 |
| Nov 6, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $116.00 |
| Nov 6, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $95.00 |
| Oct 22, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $116.00 |
Ultragenyx Pharmaceutical Inc. (RARE) Competitors
The following stocks are similar to Ultragenyx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ultragenyx Pharmaceutical Inc. (RARE) Financial Data
Ultragenyx Pharmaceutical Inc. has a market capitalization of $3.51B with a P/E ratio of -5.9x. The company generates $590.69M in trailing twelve-month revenue with a -93.0% profit margin.
Revenue growth is +28.0% quarter-over-quarter, while maintaining an operating margin of -102.6% and return on equity of -377.1%.
Valuation Metrics
Market Cap
$3.51B
Enterprise Value
$3.86B
P/E Ratio
-5.9x
PEG Ratio
-7.3x
Price/Sales
5.9x
Growth & Margins
Revenue Growth (YoY)
+28.0%
Gross Margin
+79.4%
Operating Margin
-102.6%
Net Margin
-93.0%
EPS Growth
+28.0%
Financial Health
Cash/Price Ratio
+14.0%
Current Ratio
2.4x
Debt/Equity
588.2x
ROE
-377.1%
ROA
-24.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Ultragenyx Pharmaceutical Inc. (RARE) Business Model
About Ultragenyx Pharmaceutical Inc.
What They Do
Develops treatments for rare genetic diseases.
Business Model
Ultragenyx Pharmaceutical operates by developing and commercializing novel therapies specifically for rare and ultra-rare genetic disorders. They generate revenue through the successful advancement of their products from clinical trials to market, often in collaboration with academic institutions and other pharmaceutical companies.
Additional Information
Founded in 2010 and based in Novato, California, Ultragenyx is dedicated to addressing unmet medical needs within niche markets, leveraging genetic information for precision medicine aimed at improving patient outcomes in areas often overlooked by larger pharmaceutical companies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
1,294
CEO
Dr. Emil D. Kakkis M.D., Ph.D.
Country
United States
IPO Year
2014
Website
www.ultragenyx.comUltragenyx Pharmaceutical Inc. (RARE) Latest News & Analysis
Latest News
Quick Summary
Ultragenyx (RARE) reported earnings 30 days ago; investors may want to monitor upcoming developments for potential stock movement.
Why It Matters
Ultragenyx's recent earnings report may signal potential shifts in financial performance and stock valuation, influencing investor sentiment and future trading decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Ultragenyx Pharmaceutical CEO Emil Kakkis will speak at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, at 10:00 a.m. ET.
Why It Matters
Ultragenyx's CEO speaking at a major healthcare conference signals potential insights on company strategy and pipeline developments, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
1 month ago
Quick Summary
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report, detailing its commitment to corporate responsibility and initiatives aimed at supporting rare disease communities and employees.
Why It Matters
Ultragenyx's focus on corporate responsibility and community impact may enhance its reputation, attract socially conscious investors, and potentially boost its stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Ultragenyx Pharmaceutical Inc. (RARE) held its Q1 2025 earnings call, discussing financial performance and updates on its product pipeline. Further details are available in the transcript.
Why It Matters
Ultragenyx's Q1 2025 earnings call provides insights into financial performance, growth prospects, and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
In Q1, total revenue reached $139 million, with Crysvita® generating $103 million and Dojolvi® contributing $17 million.
Why It Matters
Strong revenue figures indicate robust product performance, potentially boosting investor confidence and affecting stock valuation and future growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Ultragenyx (RARE) reported a quarterly loss of $1.57 per share, slightly worse than the estimated loss of $1.54, improving from a loss of $2.03 per share a year prior.
Why It Matters
Ultragenyx's larger-than-expected quarterly loss may indicate ongoing financial struggles, potentially impacting investor confidence and stock performance despite improved year-over-year results.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About RARE Stock
What is Ultragenyx Pharmaceutical Inc.'s (RARE) stock forecast for 2025?
Based on our analysis of 32 Wall Street analysts, Ultragenyx Pharmaceutical Inc. (RARE) has a median price target of $86.00. The highest price target is $136.00 and the lowest is $39.00.
Is RARE stock a good investment in 2025?
According to current analyst ratings, RARE has 19 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $37.35. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RARE stock?
Wall Street analysts predict RARE stock could reach $86.00 in the next 12 months. This represents a 130.3% increase from the current price of $37.35. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ultragenyx Pharmaceutical Inc.'s business model?
Ultragenyx Pharmaceutical operates by developing and commercializing novel therapies specifically for rare and ultra-rare genetic disorders. They generate revenue through the successful advancement of their products from clinical trials to market, often in collaboration with academic institutions and other pharmaceutical companies.
What is the highest forecasted price for RARE Ultragenyx Pharmaceutical Inc.?
The highest price target for RARE is $136.00 from Whitney Ijem at Canaccord Genuity, which represents a 264.1% increase from the current price of $37.35.
What is the lowest forecasted price for RARE Ultragenyx Pharmaceutical Inc.?
The lowest price target for RARE is $39.00 from at , which represents a 4.4% increase from the current price of $37.35.
What is the overall RARE consensus from analysts for Ultragenyx Pharmaceutical Inc.?
The overall analyst consensus for RARE is bullish. Out of 32 Wall Street analysts, 19 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $86.00.
How accurate are RARE stock price projections?
Stock price projections, including those for Ultragenyx Pharmaceutical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 20, 2025 10:51 AM UTC